Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases

Emerging small-molecule inhibitors of the Bruton’s Tyrosine Kinase (BTK): current development

(2021) Jiakuo Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

(2021) Xuewu Liang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

(2021) Ella R. Thompson et al.   Blood Advances

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

(2020) Jennifer Woyach et al.   BLOOD

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders

(2020) Pengfei Xu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects

(2020) Hong Zhou et al.   OncoTargets and Therapy

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC

(2020) Jiyeon Yun et al.   Cancer Discovery

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

(2020) Moshe Talpaz et al.   LEUKEMIA

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies

(2019) Xuewu Liang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Development of BTK inhibitors for the treatment of B-cell malignancies

(2019) Hyung-Ook Kim   ARCHIVES OF PHARMACAL RESEARCH

PF-06651600, a dual JAK3/TEC family kinase inhibitor

(2019) Hua Xu et al.   ACS Chemical Biology

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

(2019) R. Bissonnette et al.   BRITISH JOURNAL OF DERMATOLOGY

Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis

(2019) Ana B. Pavel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

(2019) Yaqi Kang et al.   Frontiers in Pharmacology

Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors

(2019) Jing Ren et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3

(2019) Yingxiu Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms

(2019) Tao Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma

(2018) Yang Ge et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Spleen tyrosine kinase inhibition ameliorates airway inflammation through modulation of NLRP3 inflammosome and Th17/Treg axis

(2018) Divyesh Patel et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

STAT3 and apoptosis challenges in cancer

(2018) Nazanin Fathi et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections

(2018) Yahui Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

(2018) Michael L. Vazquez et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat

(2018) Yu-yi Chu-Farseeva et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Histone Deacetylase Inhibitors in Cancer Therapy

(2018) Yijie Sun et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat

(2017) Lianbin Yao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

(2017) Atli Thorarensen et al.   JOURNAL OF MEDICINAL CHEMISTRY

A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model

(2017) Misato Ito et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer

(2017) Lin-Lin Cao et al.   MEDICINE

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment

(2017) Ailin Guo et al.   Oncotarget

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition

(2016) Jean-Baptiste Telliez et al.   ACS Chemical Biology

IL-4 enhances expression and function of surface IgM in CLL cells

(2016) M. M. Aguilar-Hernandez et al.   BLOOD

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia

(2016) Matthew D. Blunt et al.   CLINICAL CANCER RESEARCH

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

(2016) Eugene Guorong Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors

(2016) Xuewu Liang et al.   ACS Medicinal Chemistry Letters

Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold

(2016) Yang Ge et al.   ACS Medicinal Chemistry Letters

Epigenetic polypharmacology: from combination therapy to multitargeted drugs

(2016) Angel R. de Lera et al.   Clinical Epigenetics

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

Hypermorphic mutation of phospholipase C,  2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

(2015) T.-M. Liu et al.   BLOOD

Abstract 792: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity

(2015) Sanjeeva Reddy et al.   CANCER RESEARCH

Boron-Based Drug Design

(2015) Hyun Seung Ban et al.   CHEMICAL RECORD

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

(2015) R. A. de Claro et al.   CLINICAL CANCER RESEARCH

Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas

(2015) L Alinari et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Panobinostat: First Global Approval

(2015) Karly P. Garnock-Jones   DRUGS

Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2

(2015) Cheng-Qing Ning et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans

(2015) X. Li et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Development of Selective Covalent Janus Kinase 3 Inhibitors

(2015) Li Tan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition

(2015) Qiang Jeremy Wen et al.   NATURE MEDICINE

HDAC inhibitors still need a home run, despite recent approval

(2015) Malini Guha   NATURE REVIEWS DRUG DISCOVERY

Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma

(2015) Jiao Ma et al.   Oncotarget

Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance

(2015) Meenu Kesarwani et al.   Scientific Reports

Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors

(2014) S. C. Meyer et al.   CLINICAL CANCER RESEARCH

Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors

(2014) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo

(2014) Atsuo Tanimoto et al.   INFLAMMATION RESEARCH

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

(2014) Chul Won Jung et al.   LEUKEMIA & LYMPHOMA

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Janus kinase inhibitors in autoimmune diseases

(2013) John J O'Shea et al.   ANNALS OF THE RHEUMATIC DISEASES

Therapeutic Targeting of the JAK/STAT Pathway

(2013) Saara Aittomäki et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders

(2013) Yasuko Furumoto et al.   BIODRUGS

MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells

(2013) Lucy Liu et al.   CANCER BIOLOGY & THERAPY

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

(2013) Sook Ryun Park et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis

(2013) James Foran et al.   Clinical Lymphoma Myeloma & Leukemia

FLT3 Mutations in Myeloproliferative Neoplasms

(2013) Lindsay Williams et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Investigational Janus kinase inhibitors

(2013) Constantine S Tam et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

HDAC6 and Ovarian Cancer

(2013) Joshua Haakenson et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

(2013) L. Van Rompaey et al.   JOURNAL OF IMMUNOLOGY

Back to the future: oral targeted therapy for RA and other autoimmune diseases

(2013) John J. O'Shea et al.   Nature Reviews Rheumatology

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials

(2013) Jan A. Burger   Current Hematologic Malignancy Reports

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors

(2012) Timothy Forsyth et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling

(2012) Lucy Liu et al.   CANCER BIOLOGY & THERAPY

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

(2012) C. Qian et al.   CLINICAL CANCER RESEARCH

Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis

(2012) Anthony D. William et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein

(2012) Bikash Debnath et al.   JOURNAL OF MEDICINAL CHEMISTRY

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

(2012) Alfonso Quintás-Cardama et al.   LEUKEMIA RESEARCH

Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells

(2012) Sangkil Nam et al.   Molecular Oncology

JAK2 the future: therapeutic strategies for JAK-dependent malignancies

(2012) Lindsay M. LaFave et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

(2012) V Novotny-Diermayr et al.   Blood Cancer Journal

6-Bromoindirubin-3'-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells

(2011) L. Liu et al.   CANCER RESEARCH

FLT3-Mediated p38-MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis

(2011) C. Desterke et al.   CANCER RESEARCH

Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283

(2011) Jayne Curry et al.   CELL CYCLE

Designed Multiple Ligands for Cancer Therapy

(2011) N. M. O'Boyle et al.   CURRENT MEDICINAL CHEMISTRY

FLT3 inhibitors: a story of the old and the new

(2011) Amir Fathi et al.   CURRENT OPINION IN HEMATOLOGY

Janus kinase inhibitors

(2011) Brady L. Stein et al.   CURRENT OPINION IN ONCOLOGY

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas

(2011) Wenqing Qi et al.   INTERNATIONAL JOURNAL OF CANCER

Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia

(2011) Takayuki Ikezoe et al.   INTERNATIONAL JOURNAL OF CANCER

Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer

(2011) Anthony D. William et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

(2011) Anthony D. William et al.   JOURNAL OF MEDICINAL CHEMISTRY

Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery

(2011) Eric Marsault et al.   JOURNAL OF MEDICINAL CHEMISTRY

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

(2011) K C Goh et al.   LEUKEMIA

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment

(2010) A. J. Steele et al.   BLOOD

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets

(2010) Sanjive Qazi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells

(2010) Rogier Kersseboom et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside

(2010) Munira Shabbir et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Deactylase inhibition in myeloproliferative neoplasms

(2010) Sridurga Mithraprabhu et al.   INVESTIGATIONAL NEW DRUGS

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A

(2010) Kyle V. Butler et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation

(2010) M Buchwald et al.   LEUKEMIA

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

(2010) A. A. Dar et al.   MOLECULAR CANCER THERAPEUTICS

Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)

(2009) Christopher J. Burns et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

(2009) J. Zhou et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding

(2009) B. Sen et al.   CANCER RESEARCH

Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer

(2009) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Therapeutic prospect of Syk inhibitors

(2009) Paolo Ruzza et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

JAK3: A two-faced player in hematological disorders

(2009) Melanie G. Cornejo et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Lestaurtinib: a multi-targeted FLT3 inhibitor

(2009) Amir T Fathi et al.   Expert Review of Hematology

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Aurora kinases as an anti-cancer target

(2008) Takayuki Ikezoe   CANCER LETTERS

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†

(2008) Steven Howard et al.   JOURNAL OF MEDICINAL CHEMISTRY

The exploration of macrocycles for drug discovery — an underexploited structural class

(2008) Edward M. Driggers et al.   NATURE REVIEWS DRUG DISCOVERY

Intra-Articular Fms-Like Tyrosine Kinase 3 Ligand Expression Is a Driving Force in Induction and Progression of Arthritis

(2008) Mats Dehlin et al.   PLoS One

A Role for JAK2 Mutations in Myeloproliferative Diseases

(2007) Kelly J. Morgan et al.   Annual Review of Medicine

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma

(2007) L. T. Lam et al.   BLOOD